Otolith shape: a population marker for Atlantic herring Clupea harengus.

Otolith shape variation of seven Atlantic herring Clupea harengus populations from Canada, the Faroe Islands, Iceland, Ireland, Norway and Scotland, U.K., covering a large area of the species' distribution, was studied in order to see if otolith shape can be used to discriminate between populations. The otolith shape was obtained using quantitative shape analysis, transformed with Wavelet and analysed with multivariate methods. Significant differences were detected among the seven populations, which could be traced to three morphological structures in the otoliths. The differentiation in otolith shape between populations was not only correlated with their spawning time, indicating a strong environmental effect, but could also be due to differing life-history strategies. A model based on the shape differences discriminates with 94% accuracy between Icelandic summer spawners and Norwegian spring spawners, which are known to mix at feeding grounds. This study shows that otolith shape could become an accurate marker for C. harengus population discrimination.

Clinical evaluation of the safety and efficacy of 10% imidacloprid + 2.5% moxidectin topical solution for the treatment of ear mite (Otodectes cynotis) infestations in dogs.

A clinical field investigation was conducted to evaluate the safety and efficacy of 10% imidacloprid/2.5% moxidectin for the treatment of ear mites (Otodectes cynotis) in dogs. The study was a multi-centered, blinded, positive controlled, randomized clinical trial conducted under field conditions with privately owned pets. A total of 17 veterinary clinics enrolled cases for the study. An otoscopic examination was performed to confirm the presence of O. cynotis residing in the ear of the dog prior to enrollment. A single-dog household was enrolled in the study if the dog had 5 or more ear mites and an acceptable physical examination. A multi-dog household was eligible if at least one dog in the household had 5 or more mites and all dogs in the household had acceptable physical exams and met the inclusion criteria. Qualified households were randomly assigned to treatments to receive either 10% imidacloprid+2.5% moxidectin topical solution or topical selamectin solution (positive control product) according to a pre-designated enrollment ratio of 2:1, respectively. If more than one dog in a multiple dog household had adequate numbers of ear mites, one dog was randomly selected to represent the household for efficacy evaluation prior to treatment. Treatments were administered twice per label and dose banding directions for each product approximately 28 days apart (Days 0 and 28), by the dog's owner at the study site. All dogs in a household were treated on the same day and with the same product. The owners completed a post-treatment observation form one day after each treatment. Post-treatment otoscopic examinations were performed by the investigators or attending veterinarian on Days 28 and 56. Physical examinations were performed on Days 0 and 56. One hundred and four (104) households were evaluated for efficacy on SD 28, and 102 households were evaluated for efficacy on SD 56. The dogs' ages ranged from 2 months to 16 years. A total of 247 dogs were evaluated for safety. Percent efficacy was based on the percentage of dogs cleared of ear mites. Mite clearance on Day 28 was 71% for the imidacloprid+moxidectin group and 69% for the selamectin group. Mite clearance on Day 56 was 82% for the imidacloprid+moxidectin group and 74% for the selamectin group. No serious adverse events associated with either product were observed during the study. The study demonstrated that 10% imidacloprid+2.5% moxidectin applied using two topical treatments, 28 days apart, was safe and achieved similar efficacy against O. cynotis as selamectin treatments applied and evaluated under the same conditions.

Effect of antenatal exposure to paroxetine (paxil) on growth and physical maturation of mice offspring.

OBJECTIVE: Our purpose was to determine, in a placebo-controlled manner, whether antenatal exposure to paroxetine affected long-term growth and physical maturation of mice offspring. METHODS: Forty-one CD-1 mice consumed paroxetine (n = 21) or a placebo (n = 20) for 2 weeks before conception and throughout gestation. The daily dose of paroxetine (Paxil; 30 mg/kg/d) was known to achieve concentrations in the serum equivalent to the upper therapeutic level in humans and in the fetal brain equivalent to that of the adult mouse. Growth and physical maturation of the offspring were compared by paired t-test, Welch's corrected test, and Fisher's exact test. RESULTS: The maternal weight gain, litter sizes, number of fetal resorptions, and gestational age at delivery were not different between the paroxetine and the placebo-exposed offspring. Newborn pups exposed to paroxetine were more likely to have low birthweights (1.65 gm vs. 1.70 gm; P < 0.05) and narrower heads (7.7 mm vs. 8.1 mm; P < 0.05). Body weight, body length, and head circumference measurements increased in a manner that was indistinguishable between the two groups of offspring, regardless of gender. No differences in achievement of physical milestones (lower incisor eruption, eye opening, and development of external genitalia) were noted between the two groups. The reproductive capability and the perinatal outcomes of the second-generation offspring were unaffected by paroxetine exposure. CONCLUSION: A clinically relevant dose of paroxetine, when given throughout gestation, did not affect long-term growth and physical maturation of mice offspring.

TBT in marine sediments and blue mussels (Mytilus edulis) from central-west Greenland.

Concentrations of butyltin compounds were investigated in the bivalve Mytilus edulis (five sites) and marine sediments (three sites) near the largest town, Nuuk, in Greenland. In seven of the eight samples the extremely toxic compound tributyltin (TBT) was detected. The concentrations of tributyltin and degradation products in the bivalves were close to 1 microgram kg-1 wet weight (ww), calculated as Sn, which is lower than those found in Iceland and the Faeroe Islands. In sediments the concentration of TBT ranged from below the limit of detection of 1 microgram kg-1 to 171 micrograms kg-1 dry weight (dw), calculated as Sn, which is comparable to levels found in Europe.

The efficacy of ivermectin (pour-on) against the eyeworms, Thelazia gulosa and Thelazia skrjabini in naturally infected cattle.

Sixteen crossbred beef cattle, 6-8 months of age, were used to determine the efficacy of ivermectin in a pour-on formulation against natural infections of Thelazia spp. Cattle were weighed on Day 0, ranked in descending order by bodyweight and sequentially paired. Within each pair, one animal was randomly assigned to an untreated control group, while the other animal was treated with a pour-on formulation of ivermectin applied topically at 1.0 ml per 10 kg bodyweight to achieve a dosage of 500 mg ivermectin kg-1 body weight. On Day 14 all animals in both treatment groups were slaughtered. The eyes and surrounding tissues were removed and examined for eyeworms. A total of 86 adult worms (74 Thelazia skrjabini and 12 Thelazia gulosa) were recovered from the untreated control animals. T. skrjabini was found in seven, and T. gulosa in three, of the eight untreated control animals. Two T. skrjabini, one from each of two animals, were found on the surface of the eyes of cattle that had received ivermectin treatment. The reduction in the geometric mean number for T. gulosa collected from treated animals was 100% (P > 0.1) relative to controls, and 97.02% (P = 0.0025) for T. skrjabini relative to controls.